

# Albert J Czaja

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4800950/albert-j-czaja-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

280  
papers

20,926  
citations

78  
h-index

135  
g-index

300  
ext. papers

23,801  
ext. citations

6.1  
avg, IF

7.37  
L-index

#	Paper	IF	Citations
280	Advancing Biologic Therapy for Refractory Autoimmune Hepatitis.. <i>Digestive Diseases and Sciences</i> , <b>2022</b> , 1	4	1
279	Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 66, 2493-2512	4	4
278	Immune Inhibitory Properties and Therapeutic Prospects of Transforming Growth Factor-Beta and Interleukin 10 in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 1	4	2
277	Incorporating mucosal-associated invariant T cells into the pathogenesis of chronic liver disease. <i>World Journal of Gastroenterology</i> , <b>2021</b> , 27, 3705-3733	5.6	3
276	Review article: targeting the B cell activation system in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 902-922	6.1	2
275	Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 1286-1304	6.1	4
274	Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta-Analyses Supporting American Association for the Study of Liver Diseases Guidelines. <i>Hepatology</i> , <b>2020</b> , 72, 753-769	11.2	15
273	Autoimmune Hepatitis: Surviving Crises of Doubt and Elimination. <i>Clinical Liver Disease</i> , <b>2020</b> , 15, S72-S81.2		1
272	Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. <i>Hepatology</i> , <b>2020</b> , 72, 671-722	11.2	198
271	Letter: high ferritin to haemoglobin ratio is related to early mortality in patients with alcoholic hepatitis - authorS reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 1457-1458	6.1	
270	Letter: severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis-offender or bystander? AuthorsSreply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 959-960	6.1	
269	Letter: vitamin D deficiency and autoimmune hepatitis - from research to treatment-authorsSreply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 1104-1105	6.1	
268	Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. <i>Autoimmunity</i> , <b>2019</b> , 52, 144-160	3	9
267	Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 6579-6606	5.6	13
266	Review article: iron disturbances in chronic liver diseases other than haemochromatosis - pathogenic, prognostic, and therapeutic implications. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 681-701	6.1	19
265	Evolving Role of Vitamin D in Immune-Mediated Disease and Its Implications in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 324-344	4	23
264	Recurrent and De Novo Autoimmune Hepatitis. <i>Liver Transplantation</i> , <b>2019</b> , 25, 152-166	4.5	37

263	Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 173-182	6.1	29
262	Autoimmune Hepatitis and Immune-Mediated Cholestatic Liver Diseases <b>2019</b> , 251-305		
261	Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 1706-1725	4	11
260	Autoimmune hepatitis. <i>Nature Reviews Disease Primers</i> , <b>2018</b> , 4, 18017	51.1	140
259	Epigenetic changes and their implications in autoimmune hepatitis. <i>European Journal of Clinical Investigation</i> , <b>2018</b> , 48, e12899	4.6	21
258	Emerging therapeutic biomarkers of autoimmune hepatitis and their impact on current and future management. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2018</b> , 12, 547-564	4.2	10
257	Evolving paradigm of treatment for autoimmune hepatitis. <i>Expert Review of Clinical Immunology</i> , <b>2017</b> , 13, 781-798	5.1	10
256	Autoimmune Hepatitis Overlap Syndromes and Liver Pathology. <i>Gastroenterology Clinics of North America</i> , <b>2017</b> , 46, 345-364	4.4	12
255	Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 859-868	5.6	40
254	Review article: next-generation transformative advances in the pathogenesis and management of autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 920-937	6.1	19
253	Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2017</b> , 62, 2277-2292	4	39
252	Overlap Syndromes of Primary Sclerosing Cholangitis <b>2017</b> , 41-57		
251	Autoimmune Liver Diseases: Autoimmune Hepatitis <b>2017</b> , 217-250		
250	Autoimmune Liver Diseases: Overlap Syndromes <b>2017</b> , 307-328		
249	Targeting Hepatic Fibrosis in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2016</b> , 61, 3118-3139		22
248	Nature and Implications of Oxidative and Nitrosative Stresses in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2016</b> , 61, 2784-2803	4	17
247	Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions. <i>Gut and Liver</i> , <b>2016</b> , 10, 177-203	4.8	81
246	2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. <i>American Journal of Transplantation</i> , <b>2016</b> , 16, 2816-2835	8.7	275

245	Adoptive cell transfer in autoimmune hepatitis. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2015</b> , 9, 821-36	4.2	10
244	Letter: reversibility of hepatic fibrosis and immunosuppression withdrawal in patients with autoimmune hepatitis/primary biliary cirrhosis overlap syndrome - author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 794-5	6.1	
243	Cell mediators of autoimmune hepatitis and their therapeutic implications. <i>Digestive Diseases and Sciences</i> , <b>2015</b> , 60, 1528-42	4	26
242	Diagnosis and management of autoimmune hepatitis. <i>Clinics in Liver Disease</i> , <b>2015</b> , 19, 57-79	4.6	37
241	Transitioning from Idiopathic to Explainable Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2015</b> , 60, 2881-900	4	35
240	Cholestatic phenotypes of autoimmune hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 1430-8	6.9	41
239	Letter: guidelines for the management of autoimmune hepatitis - author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 115-6	6.1	
238	Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 385-406	6.1	50
237	Current and prospective pharmacotherapy for autoimmune hepatitis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 1715-36	4	26
236	Review article: permanent drug withdrawal is desirable and achievable for autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 1043-58	6.1	22
235	Review article: chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 40, 261-79	6.1	50
234	Targeting apoptosis in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2014</b> , 59, 2890-904	4	32
233	Hepatic inflammation and progressive liver fibrosis in chronic liver disease. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 2515-32	5.6	213
232	Overlap syndromes. <i>Clinical Liver Disease</i> , <b>2014</b> , 3, 2-5	2.2	9
231	Review article: the management of autoimmune hepatitis beyond consensus guidelines. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 343-64	6.1	45
230	Management of Recalcitrant Autoimmune Hepatitis. <i>Current Hepatitis Reports</i> , <b>2013</b> , 12, 66-77		4
229	Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2013</b> , 58, 1459-76	4	35
228	The overlap syndromes of autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2013</b> , 58, 326-43	4	53

227	Acute and acute severe (fulminant) autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2013</b> , 58, 897-914	4.1	90
226	Autoimmune hepatitis in diverse ethnic populations and geographical regions. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2013</b> , 7, 365-85	4.2	44
225	Letter: treatment of autoimmune acute liver failure--beyond consensus guidelines; author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 1144	6.1	
224	Diagnosis and management of the overlap syndromes of autoimmune hepatitis. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2013</b> , 27, 417-23		45
223	Challenges in the diagnosis and management of autoimmune hepatitis. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2013</b> , 27, 531-9		14
222	Current management strategies for hepatocellular carcinoma. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2013</b> , 59, 143-59	1.6	3
221	Autoantibody-negative autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2012</b> , 57, 610-24	4	56
220	Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 691-707	6.1	50
219	Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation. <i>Digestive Diseases and Sciences</i> , <b>2012</b> , 57, 2248-66	4	70
218	Advances in the current treatment of autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2012</b> , 57, 1996-2010	4	40
217	Drug choices in autoimmune hepatitis: part B--Nonsteroids. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2012</b> , 6, 617-35	4.2	29
216	Drug choices in autoimmune hepatitis: part A--Steroids. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2012</b> , 6, 603-15	4.2	28
215	Autoimmune hepatitis: focusing on treatments other than steroids. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2012</b> , 26, 615-20		31
214	Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. <i>Liver International</i> , <b>2012</b> , 32, 85-92	7.9	54
213	Nonstandard drugs and feasible new interventions for autoimmune hepatitis: part II. <i>Inflammation and Allergy: Drug Targets</i> , <b>2012</b> , 11, 351-63		13
212	Nonstandard drugs and feasible new interventions for autoimmune hepatitis: part I. <i>Inflammation and Allergy: Drug Targets</i> , <b>2012</b> , 11, 337-50		15
211	Comparability of probable and definite autoimmune hepatitis by international diagnostic scoring criteria. <i>Gastroenterology</i> , <b>2011</b> , 140, 1472-80	13.3	37
210	Autoimmune hepatitis in special patient populations. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2011</b> , 25, 689-700	2.5	30

209	Performance parameters of the conventional serological markers for autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2011</b> , 56, 545-54	4	51
208	Drug-induced autoimmune-like hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2011</b> , 56, 958-76	4	178
207	Cryptogenic chronic hepatitis and its changing guise in adults. <i>Digestive Diseases and Sciences</i> , <b>2011</b> , 56, 3421-38	4	36
206	Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. <i>Current Pharmaceutical Design</i> , <b>2011</b> , 17, 3120-40	3.3	31
205	Difficult treatment decisions in autoimmune hepatitis. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 934-46	4.6	54
204	Animal models of autoimmune hepatitis. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2010</b> , 4, 429-43	4.2	20
203	Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. <i>Gastroenterology</i> , <b>2010</b> , 139, 58-72.e4	13.3	211
202	PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , <b>2010</b> , 35, 436-42	15.5	103
201	Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 2712-26	4	24
200	Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 1761-9	4	23
199	Autoantibodies as prognostic markers in autoimmune liver disease. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 2144-61	4	63
198	Diagnosis and management of autoimmune hepatitis. <i>Hepatology</i> , <b>2010</b> , 51, 2193-213	11.2	979
197	Putting flesh and polish on autoimmune hepatitis and moving the disease of exclusion to inclusion. <i>Hepatology</i> , <b>2010</b> , 52, 1177-84	11.2	2
196	Reply:. <i>Hepatology</i> , <b>2010</b> , 52, 1857-1858	11.2	0
195	Current and future treatments of autoimmune hepatitis. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2009</b> , 3, 269-91	4.2	45
194	Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. <i>Seminars in Liver Disease</i> , <b>2009</b> , 29, 315-30	7.3	39
193	Features and consequences of untreated type 1 autoimmune hepatitis. <i>Liver International</i> , <b>2009</b> , 29, 816-23	7.9	52
192	Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 161-7	13.4	85

191	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , <b>2009</b> , 25, 215-22	3	18
190	Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. <i>World Journal of Gastroenterology</i> , <b>2009</b> , 15, 2314-28	5.6	30
189	Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2008</b> , 6, 379-88	6.9	73
188	Chapter 11 Immunopathogenesis of Autoimmune Liver Damage. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2008</b> , 8, 121-139	0.3	1
187	Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. <i>Drugs and Aging</i> , <b>2008</b> , 25, 219-39	4.7	34
186	Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 1944-51	0.7	68
185	Safety issues in the management of autoimmune hepatitis. <i>Expert Opinion on Drug Safety</i> , <b>2008</b> , 7, 319-321	4.1	83
184	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , <b>2008</b> , 24, 298-305	3	14
183	Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis. <i>Journal of Clinical Gastroenterology</i> , <b>2008</b> , 42, 1047-53	3	45
182	HLA DRB1*13 as a risk factor for type 1 autoimmune hepatitis in North American patients. <i>Digestive Diseases and Sciences</i> , <b>2008</b> , 53, 522-8	4	16
181	Simplified criteria for the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , <b>2008</b> , 48, 169-76	11.2	1166
180	Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. <i>Hepatology</i> , <b>2008</b> , 48, 1540-8	11.2	132
179	Arthur Joseph McCullough, Jr., 58th President, AASLD. <i>Hepatology</i> , <b>2008</b> , 47, 775-6	11.2	
178	Progress in the diagnosis and treatment of autoimmune hepatitis. <i>Minerva Medica</i> , <b>2008</b> , 99, 549-68	2.2	6
177	Current therapy for autoimmune hepatitis. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , <b>2007</b> , 4, 202-14		32
176	Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, 1005-12	0.7	125
175	Optimizing diagnosis from the medical liver biopsy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2007</b> , 5, 898-907	6.9	40
174	Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. <i>Hepatology</i> , <b>2007</b> , 46, 1138-45	11.2	113

173	A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. <i>Tissue Antigens</i> , <b>2007</b> , 69, 227-35		60
172	Consequences of treatment withdrawal in type 1 autoimmune hepatitis. <i>Liver International</i> , <b>2007</b> , 27, 507-15	7.9	81
171	Evidence of a genetic basis for the different geographic occurrences of liver/kidney microsomal antibody type 1 in hepatitis C. <i>Digestive Diseases and Sciences</i> , <b>2007</b> , 52, 179-84	4	20
170	Autoimmune hepatitis. Part A: pathogenesis. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2007</b> , 1, 113-28	4.2	60
169	Autoimmune hepatitis. Part B: diagnosis. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2007</b> , 1, 129-43	4.2	23
168	Autoimmune liver disease and rheumatic manifestations. <i>Current Opinion in Rheumatology</i> , <b>2007</b> , 19, 74-80	5.3	11
167	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , <b>2007</b> , 23, 255-62	3	13
166	Evolving concepts in the diagnosis, pathogenesis and treatment of autoimmune hepatitis. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2007</b> , 53, 43-78	1.6	11
165	Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. <i>Hepatology</i> , <b>2006</b> , 43, 532-8	11.2	146
164	Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis. <i>Autoimmunity</i> , <b>2006</b> , 39, 341-8	3	14
163	The role of autoantibodies as diagnostic markers of autoimmune hepatitis. <i>Expert Review of Clinical Immunology</i> , <b>2006</b> , 2, 33-48	5.1	13
162	Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a foray across diagnostic boundaries. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 251-2	13.4	34
161	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , <b>2006</b> , 22, 234-40	3	12
160	Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4. <i>Liver International</i> , <b>2006</b> , 26, 552-8	7.9	26
159	Clinical significance of HLA DRB103-DRB104 in type 1 autoimmune hepatitis. <i>Liver International</i> , <b>2006</b> , 26, 1201-8	7.9	25
158	Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2006</b> , 51, 968-75	4	56
157	Autoimmune hepatitis—approach to diagnosis. <i>MedGenMed: Medscape General Medicine</i> , <b>2006</b> , 8, 55		10
156	Current Advances in the Treatment of Autoimmune Hepatitis. <i>Gastroenterology and Hepatology</i> , <b>2006</b> , 2, 107-110	0.7	1



155	Chronic Hepatitis <b>2006</b> , 729-747		4
154	Autoantibodies in autoimmune liver disease. <i>Advances in Clinical Chemistry</i> , <b>2005</b> , 40, 127-64	5.8	38
153	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , <b>2005</b> , 21, 293-9	3	6
152	Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. <i>Journal of Clinical Gastroenterology</i> , <b>2005</b> , 39, 819-25	3	74
151	Anti-tRNP(ser)sec/SLA/LP autoantibodies. Comparative study using in-house ELISA with a recombinant 48.8 kDa protein, immunoblot, and analysis of immunoprecipitated RNAs. <i>Liver International</i> , <b>2005</b> , 25, 410-9	7.9	17
150	Treatment challenges and investigational opportunities in autoimmune hepatitis. <i>Hepatology</i> , <b>2005</b> , 41, 207-15	11.2	71
149	Current concepts in autoimmune hepatitis. <i>Annals of Hepatology</i> , <b>2005</b> , 4, 6-24	3.1	48
148	Current concepts in autoimmune hepatitis. <i>Annals of Hepatology</i> , <b>2005</b> , 4, 6-24	3.1	13
147	Diverse manifestations and evolving treatments of autoimmune hepatitis. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2005</b> , 51, 313-33	1.6	26
146	Nonstandard antibodies as prognostic markers in autoimmune hepatitis. <i>Autoimmunity</i> , <b>2004</b> , 37, 195-201	3.1	47
145	Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. <i>Liver International</i> , <b>2004</b> , 24, 322-9	7.9	67
144	TrueSantimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?. <i>Clinical and Experimental Immunology</i> , <b>2004</b> , 135, 154-8	6.2	74
143	Frequency and significance of antibodies to <i>Saccharomyces cerevisiae</i> in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2004</b> , 49, 611-8	4	15
142	Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. <i>Hepatology</i> , <b>2004</b> , 39, 1631-8	8.2	97
141	Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>2004</b> , 40, 646-52	13.4	187
140	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , <b>2004</b> , 20, 231-40	3	9
139	Autoimmune Liver Disease <b>2004</b> , 121-125		
138	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , <b>2003</b> , 19, 232-42	3	11

137	Autoantibodies in the diagnosis and management of liver disease. <i>Journal of Clinical Gastroenterology</i> , <b>2003</b> , 37, 315-29	3	49
136	Frequency and significance of antibodies to chromatin in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2003</b> , 48, 1658-64	4	33
135	Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. <i>Liver International</i> , <b>2003</b> , 23, 116-23	7.9	61
134	Genetic bases of autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2002</b> , 47, 2139-50	4	75
133	Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. <i>Hepatology</i> , <b>2002</b> , 35, 890-7	11.2	120
132	Diagnosis and treatment of autoimmune hepatitis. <i>Hepatology</i> , <b>2002</b> , 36, 479-97	11.2	406
131	Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. <i>Liver Transplantation</i> , <b>2002</b> , 8, 505-13	4.5	76
130	Celiac disease-associated autoimmune cholangitis. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 3196-87	6.7	23
129	Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 2051-7	0.7	108
128	Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 413-9	0.7	116
127	Emerging treatments for autoimmune hepatitis. <i>Inflammation and Allergy: Drug Targets</i> , <b>2002</b> , 1, 317-26		7
126	Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. <i>Autoimmunity</i> , <b>2002</b> , 35, 475-83	3	49
125	Treatment of autoimmune hepatitis. <i>Seminars in Liver Disease</i> , <b>2002</b> , 22, 365-78	7.3	74
124	Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. <i>Gut</i> , <b>2002</b> , 51, 259-64	19.2	119
123	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , <b>2002</b> , 18, 334-44	3	6
122	Autoimmune hepatitis. <i>Clinics in Liver Disease</i> , <b>2002</b> , 6, xi-xii	4.6	4
121	Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. <i>Journal of Hepatology</i> , <b>2002</b> , 37, 302-8	13.4	94
120	The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. <i>Clinics in Liver Disease</i> , <b>2002</b> , 6, 685-705	4.6	76

119	Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. <i>Clinics in Liver Disease</i> , <b>2002</b> , 6, 707-25	4.6	35
118	Treatment strategies in autoimmune hepatitis. <i>Clinics in Liver Disease</i> , <b>2002</b> , 6, 799-824	4.6	44
117	Shared genetic risk factors in autoimmune liver disease. <i>Digestive Diseases and Sciences</i> , <b>2001</b> , 46, 140-7	4	48
116	Autoimmune hepatitis with incidental histologic features of bile duct injury. <i>Hepatology</i> , <b>2001</b> , 34, 659-65	11.2	143
115	Recurrent autoimmune hepatitis after orthotopic liver transplantation. <i>Liver Transplantation</i> , <b>2001</b> , 7, 302-10	4.5	156
114	Understanding the pathogenesis of autoimmune hepatitis. <i>American Journal of Gastroenterology</i> , <b>2001</b> , 96, 1224-31	0.7	92
113	Autoimmune hepatitis and its variant syndromes. <i>Gut</i> , <b>2001</b> , 49, 589-94	19.2	67
112	Autoantibodies in liver disease. <i>Gastroenterology</i> , <b>2001</b> , 120, 239-49	13.3	117
111	Current concepts in the diagnosis, pathogenesis, and treatment of autoimmune hepatitis. <i>Mayo Clinic Proceedings</i> , <b>2001</b> , 76, 1237-52	6.4	32
110	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , <b>2001</b> , 17, 268-75	3	
109	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , <b>2000</b> , 16, 262-70	3	3
108	Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. <i>Hepatology</i> , <b>2000</b> , 31, 49-53	11.2	198
107	Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser) <sup>Sec</sup> complex recognized by autoantibodies from patients with type-1 autoimmune hepatitis. <i>Clinical and Experimental Immunology</i> , <b>2000</b> , 121, 364-74	6.2	111
106	Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. <i>Immunological Reviews</i> , <b>2000</b> , 174, 250-9	11.3	160
105	Nature and behavior of serum cytokines in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2000</b> , 45, 1028-35	4	37
104	Hepatocellular carcinoma in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2000</b> , 45, 1944-8	4	65
103	Autoimmune hepatitis: the investigational and clinical challenges. <i>Hepatology</i> , <b>2000</b> , 31, 1194-200	11.2	64
102	Autoimmune cholangitis within the spectrum of autoimmune liver disease. <i>Hepatology</i> , <b>2000</b> , 31, 1231-8	11.2	100

101	Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. <i>Gastroenterology</i> , <b>2000</b> , 119, 1312-6	13.3	104
100	Therapy of autoimmune diseases - state of the art <b>2000</b> , 311-324		
99	Variant forms of autoimmune hepatitis. <i>Current Gastroenterology Reports</i> , <b>1999</b> , 1, 63-70	5	32
98	Special report: Autoimmune hepatitis. <i>Current Treatment Options in Gastroenterology</i> , <b>1999</b> , 2, 423-436	2.5	2
97	Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. <i>Hepatology</i> , <b>1999</b> , 30, 851-6	11.2	148
96	Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. <i>Hepatology</i> , <b>1999</b> , 30, 1381-6	11.2	112
95	Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>1999</b> , 30, 394-401	13.4	149
94	International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>1999</b> , 31, 929-38	13.4	2240
93	Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. <i>Gastroenterology</i> , <b>1999</b> , 117, 645-52	13.3	141
92	Drug therapy in the management of type 1 autoimmune hepatitis. <i>Drugs</i> , <b>1999</b> , 57, 49-68	12.1	53
91	Viral Genotypes as Determinants of Autoimmune Expression in Chronic Hepatitis C. <i>Mayo Clinic Proceedings</i> , <b>1999</b> , 74, 454-460	6.4	17
90	Immune phenotype of chronic liver disease. <i>Digestive Diseases and Sciences</i> , <b>1998</b> , 43, 2149-55	4	52
89	Frequency and significance of phenotypes for alpha1-antitrypsin deficiency in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>1998</b> , 43, 1725-31	4	16
88	Antibodies to Ro/La, Cenp-B, and snRNPs antigens in autoimmune hepatitis of North America versus Asia: patterns of immunofluorescence, ELISA reactivities, and HLA association. <i>Digestive Diseases and Sciences</i> , <b>1998</b> , 43, 1322-31	4	28
87	Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>1998</b> , 43, 2190-5	4	128
86	Characterization of anti-histone antibodies in patients with type 1 autoimmune hepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>1998</b> , 13, 483-9	4	33
85	Frequency and nature of the variant syndromes of autoimmune liver disease. <i>Hepatology</i> , <b>1998</b> , 28, 360-5	11.2	272
84	Host- and disease-specific factors affecting steatosis in chronic hepatitis C. <i>Journal of Hepatology</i> , <b>1998</b> , 29, 198-206	13.4	215

83	GB virus-C infection in type 1 autoimmune hepatitis. <i>Mayo Clinic Proceedings</i> , <b>1998</b> , 73, 412-8	6.4	4
82	GB virus-C infection in type 1 autoimmune hepatitis.. <i>Mayo Clinic Proceedings</i> , <b>1998</b> , 73, 412-418	6.4	5
81	Extrahepatic immunologic features of chronic viral hepatitis. <i>Digestive Diseases</i> , <b>1997</b> , 15, 125-44	3.2	33
80	Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. <i>Gastroenterology</i> , <b>1997</b> , 112, 2028-35	13.3	216
79	Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>1997</b> , 42, 1688-96	4	66
78	Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. <i>Hepatology</i> , <b>1997</b> , 25, 317-23	11.2	227
77	Histological findings in chronic hepatitis C with autoimmune features. <i>Hepatology</i> , <b>1997</b> , 26, 459-66	11.2	76
76	Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. <i>Hepatology</i> , <b>1997</b> , 26, 567-72	11.2	75
75	Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis <b>1997</b> , 26, 567		5
74	Genetic distinctions between types 1 and 2 autoimmune hepatitis. <i>American Journal of Gastroenterology</i> , <b>1997</b> , 92, 2197-200	0.7	52
73	Diagnosis and therapy of autoimmune liver disease. <i>Medical Clinics of North America</i> , <b>1996</b> , 80, 973-94	7	39
72	Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. <i>Gastroenterology</i> , <b>1996</b> , 110, 848-57	13.3	239
71	Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>1996</b> , 24, 52-9	13.4	91
70	The variant forms of autoimmune hepatitis. <i>Annals of Internal Medicine</i> , <b>1996</b> , 125, 588-98	8	158
69	Validation of scoring system for diagnosis of autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>1996</b> , 41, 305-14	4	106
68	Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>1996</b> , 41, 1733-40	4	57
67	Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. <i>Hepatology</i> , <b>1996</b> , 24, 1068-73	11.2	163
66	Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis <b>1996</b> , 24, 1068		4

65	Significance of human leukocyte antigens DR3 and DR4 in chronic viral hepatitis. <i>Digestive Diseases and Sciences</i> , <b>1995</b> , 40, 2098-106	4	26
64	Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>1995</b> , 40, 33-40	4	31
63	Autoimmune hepatitis. Evolving concepts and treatment strategies. <i>Digestive Diseases and Sciences</i> , <b>1995</b> , 40, 435-56	4	138
62	Autoantibodies. <i>Baillieres Clinical Gastroenterology</i> , <b>1995</b> , 9, 723-44		20
61	Immunologic features and HLA associations in chronic viral hepatitis. <i>Gastroenterology</i> , <b>1995</b> , 108, 157-64	3.3	111
60	High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. <i>Gastroenterology</i> , <b>1995</b> , 108, 1159-66	13.3	144
59	Frequency and significance of antibodies to histones in autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>1995</b> , 23, 32-8	13.4	48
58	Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations. <i>American Journal of Surgical Pathology</i> , <b>1995</b> , 19, 699-708	6.7	93
57	The validity and importance of subtypes in autoimmune hepatitis: a point of view. <i>American Journal of Gastroenterology</i> , <b>1995</b> , 90, 1206-11	0.7	130
56	The nature and prognostic implications of autoimmune hepatitis with an acute presentation. <i>Journal of Hepatology</i> , <b>1994</b> , 21, 866-71	13.4	135
55	Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. <i>Gastroenterology</i> , <b>1994</b> , 107, 200-7	13.3	106
54	Autoimmune hepatitis and viral infection. <i>Gastroenterology Clinics of North America</i> , <b>1994</b> , 23, 547-66	4.4	13
53	Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. <i>Journal of Hepatology</i> , <b>1993</b> , 18, 342-52	13.4	87
52	Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis. A prospective randomized treatment trial evaluating clinical, biochemical, and lymphocyte subset responses. <i>Journal of Hepatology</i> , <b>1993</b> , 17, 180-6	13.4	18
51	Chronic active hepatitis: the challenge for a new nomenclature. <i>Annals of Internal Medicine</i> , <b>1993</b> , 119, 510-7	8	49
50	Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. <i>Gastroenterology</i> , <b>1993</b> , 105, 1824-32	13.3	253
49	The nature and prognosis of severe cryptogenic chronic active hepatitis. <i>Gastroenterology</i> , <b>1993</b> , 104, 1755-61	13.3	93
48	Significance of HLA DR4 in type 1 autoimmune hepatitis. <i>Gastroenterology</i> , <b>1993</b> , 105, 1502-7	13.3	168

47	Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. <i>Gastroenterology</i> , <b>1993</b> , 105, 1522-8	13.3	123
46	Genetic predispositions for the immunological features of chronic active hepatitis. <i>Hepatology</i> , <b>1993</b> , 18, 816-22	11.2	105
45	Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. <i>Gastroenterology</i> , <b>1992</b> , 103, 1290-5	13.3	179
44	Duration and specificity of antibodies to hepatitis C virus in chronic active hepatitis. <i>Gastroenterology</i> , <b>1992</b> , 102, 1675-9	13.3	16
43	Frequency of antibody to hepatitis C virus in asymptomatic HBsAg-negative chronic active hepatitis. <i>Journal of Hepatology</i> , <b>1992</b> , 14, 88-93	13.4	25
42	Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>1992</b> , 14, 325-31	13.4	126
41	Sequential histologic evaluations in collagenous colitis. Correlations with disease behavior and sampling strategy. <i>Digestive Diseases and Sciences</i> , <b>1992</b> , 37, 1903-9	4	141
40	Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. <i>Hepatology</i> , <b>1992</b> , 15, 215-21	11.2	153
39	Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated autoimmune chronic active hepatitis. <i>Mayo Clinic Proceedings</i> , <b>1991</b> , 66, 572-82	6.4	32
38	Clinical and prognostic implications of HLA B8 in corticosteroid-treated severe autoimmune chronic active hepatitis. <i>Gastroenterology</i> , <b>1990</b> , 98, 1587-93	13.3	53
37	Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. <i>Hepatology</i> , <b>1990</b> , 11, 1044-9	11.2	59
36	Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis. <i>Mayo Clinic Proceedings</i> , <b>1990</b> , 65, 23-30	6.4	44
35	Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated cryptogenic chronic active hepatitis. <i>Mayo Clinic Proceedings</i> , <b>1990</b> , 65, 1303-13	6.4	15
34	Auto-immune chronic active hepatitis: a specific entity? The negative argument. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>1990</b> , 5, 343-51	4	25
33	The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. <i>Hepatology</i> , <b>1989</b> , 9, 193-7	11.2	108
32	Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. <i>Hepatology</i> , <b>1989</b> , 10, 39-43	11.2	54
31	Prognosis of corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis in postmenopausal women: a retrospective analysis. <i>Gastroenterology</i> , <b>1989</b> , 97, 1288-93	13.3	25
30	Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis. <i>Hepatology</i> , <b>1988</b> , 8, 1679-83	11.2	63

29	Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. <i>Gastroenterology</i> , <b>1988</b> , 95, 448-53	13.3	104
28	Diagnosis and management of chronic active hepatitis B. <i>Comprehensive Therapy</i> , <b>1988</b> , 14, 46-53		
27	Frequency and significance of serum alpha-fetoprotein elevation in severe hepatitis B surface antigen-negative chronic active hepatitis. <i>Gastroenterology</i> , <b>1987</b> , 93, 687-92	13.3	16
26	Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. <i>Gastroenterology</i> , <b>1987</b> , 92, 215-9	13.3	84
25	Frequency and significance of antibody to double-stranded DNA in chronic active hepatitis. <i>Hepatology</i> , <b>1986</b> , 6, 976-80	11.2	26
24	Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. <i>Digestive Diseases and Sciences</i> , <b>1986</b> , 31, 705-11	4	98
23	How lupoid is lupoid hepatitis?. <i>Journal of Rheumatology</i> , <b>1986</b> , 13, 95-8	4.1	19
22	Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology. <i>Liver</i> , <b>1984</b> , 4, 105-16		97
21	Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. <i>Gastroenterology</i> , <b>1984</b> , 87, 1222-1227	13.3	74
20	Natural history, clinical features, and treatment of autoimmune hepatitis. <i>Seminars in Liver Disease</i> , <b>1984</b> , 4, 1-12	7.3	138
19	Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. <i>Hepatology</i> , <b>1984</b> , 4, 622-7	11.2	142
18	Liver blood flow using clearance techniques. <i>Hepatology</i> , <b>1984</b> , 4, 746	11.2	
17	Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. <i>Gastroenterology</i> , <b>1984</b> , 87, 1222-7	13.3	15
16	Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. <i>Gastroenterology</i> , <b>1983</b> , 85, 713-717	13.3	138
15	Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. <i>Gastroenterology</i> , <b>1983</b> , 85, 713-7	13.3	27
14	Prognostic and therapeutic implications of extreme serum aminotransferase elevation in chronic active hepatitis. <i>Mayo Clinic Proceedings</i> , <b>1982</b> , 57, 303-9	6.4	25
13	Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: Correlation of serum transaminase and gamma globulin levels with histologic features. <i>Gastroenterology</i> , <b>1981</b> , 80, 687-692	13.3	115
12	Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. <i>New England Journal of Medicine</i> , <b>1981</b> , 304, 5-9	59.2	115



11	Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. <i>Gastroenterology</i> , <b>1981</b> , 80, 687-92	13.3	26
10	Current problems in the diagnosis and management of chronic active hepatitis. <i>Mayo Clinic Proceedings</i> , <b>1981</b> , 56, 311-23	6.4	17
9	Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. <i>Gastroenterology</i> , <b>1980</b> , 78, 518-523	13.3	111
8	Systemic mycosis complicating high dose corticosteroid treatment of chronic active liver disease. <i>American Journal of Gastroenterology</i> , <b>1980</b> , 74, 428-32	0.7	11
7	Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. <i>Gastroenterology</i> , <b>1980</b> , 78, 518-23	13.3	22
6	Clinical assessment of cirrhosis in severe chronic active liver disease: specificity and sensitivity of physical and laboratory findings. <i>Mayo Clinic Proceedings</i> , <b>1980</b> , 55, 360-4	6.4	28
5	Development and early prognosis of esophageal varices in severe chronic active liver disease (CALD) treated with prednisone. <i>Gastroenterology</i> , <b>1979</b> , 77, 629-633	13.3	37
4	Development and early prognosis of esophageal varices in severe chronic active liver disease (CALD) treated with prednisone. <i>Gastroenterology</i> , <b>1979</b> , 77, 629-33	13.3	8
3	Malignancy in Chronic Liver Disease. <i>Gastroenterology</i> , <b>1977</b> , 73, 192-193	13.3	10
2	Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. <i>The American Journal of Digestive Diseases</i> , <b>1977</b> , 22, 973-80		73
1	Autoimmune hepatitis: clinical and laboratory diagnosis 153-170		1